Genentech, Inc.

Amgen Inc.

Other

Brian Drake Bennett

William Matthews

David V Goeddel

Jonathan Phillips

William I Wood

Chadwick Terence King

James M Lee

Martin Citron

Robert James Vassar

Siao Ping Tsai

William Albert Matthews

Francis C Zeigler

Chadwick T King

Susan D Broz

Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.

Anti-Jagged1 antigen binding proteins

Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides.

Beta secretase genes

Beta secretase polypeptides

Agonist antibodies are disclosed which bind to the extracellular domain of receptor protein tyrosine kinases pTKs, and thereby cause dimerization and activation of the intracellular tyrosine kinase domain thereof. The antibodies are useful for activating their respective receptor and thereby enabling the role of the tyrosine kinase receptor in cell growth and/or differentiation to be studied. Chimeric proteins comprising the extracellular domain of the receptor pTKs and an immunoglobulin constant domain sequence are also disclosed.

SAL-S1 receptor protein tyrosine kinase agonist antibodies

The WSX receptor, WSX receptor extracellular domain (ECD), WSX receptor variants, chimeric WSX receptor (e.g., WSX receptor immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described.

Leptin receptor having a WSX motif

Protein tyrosine kinase agonist antibodies

Agonist antibodies are disclosed which bind to the extracellular domain of the flk2/flt3 receptor and thereby activate the intracellular kinase domain thereof. The labeled antibodies are useful as diagnostics for detecting the presence of the flk2/flt3 receptor in primitive hematopoietic cells for example. The antibodies are able to cause primitive hematopoietic cells to proliferate and/or differentiate and thereby enhance repopulation of mature blood cell lineages in a mammal which has undergone chemo- or radiation therapy or bone marrow transplantation. The antibodies are further useful for treating mammals which have suffered a decrease in blood cells as a consequence of disease or a hemorrhage, for example.

Agonist antibodies against the flk2/flt3 receptor and uses thereof

A novel hepatoma transmembrane kinase receptor ligand (Htk ligand) which binds to, and activates, the Htk receptor is disclosed. As examples, mouse and human Htk ligands have been identified in a variety of tissues using a soluble Htk-Fc fusion protein. The ligands have been cloned and sequenced. The invention also relates to nucleic acids encoding the ligand, methods for production and use of the ligand, and antibodies directed thereto.

HTK ligand

Method for using Htk ligand

Growing community of inventors

Thousand Oaks, CA, United States of America

Brian Drake Bennett